Roche's Tecentriq wins speedy US review in small cell lung cancer

Roche's Tecentriq wins speedy US review in small cell lung cancer

Roche's Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company said, setting up possible approval by March 18.

Logo of Swiss drugmaker Roche is seen at its headquarters in Basel
The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann

ZURICH: Roche's Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company said, setting up possible approval by March 18.

Wednesday's announcement comes after Roche in September said patients with untreated extensive-stage SCLC, where cancer has spread, lived a median 12.3 months after getting Tecentriq plus chemotherapy, compared to 10.3 months for those on just chemotherapy.

(Reporting by John Miller; editing by Thomas Seythal)

Source: Reuters

Bookmark